Johnson & Johnson shares fall after company beats on earnings and revenue, but lowers pharmaceutical sales guidance
Publishing timestamp: 2023-04-18 10:50:01
Summary
Johnson & Johnson reported adjusted earnings and revenue that beat expectations, raised full-year guidance, but lowered sales guidance for pharmaceutical business. Company's stock fell after the report. J&J is forecasting higher sales and earnings for 2023, with growth across all business sectors. The company is making progress on separating its consumer health business and has proposed a settlement for talc-related lawsuits.
Sentiment: MIXED
Tickers: JNJ,
Keywords: dividends, breaking news, biotech and pharmaceuticals, pharmaceuticals, johnson & johnson, business news, earnings, health care industry, biotechnology, breaking news: earnings, breaking news: business,
Source: https://www.cnbc.com/2023/04/18/johnson-johnson-jnj-earnings-q1-2023.html